News | August 22, 2012

Improved Radiation Technique Offers Treatment for In-stent Restenosis

Radiation can improve outcomes in peripheral stenting


August 22, 2012 — Placement of an endovascular stent has become a common procedure for successfully reopening blocked arteries. Even so, the treated vessel may once again narrow (restenosis), restricting blood flow. In the femoral and popliteal arteries in the leg, the use of nitinol stents magnifies this problem, and about 20 to 40 percent of these stent patients experience restenosis two years after angioplasty. Now, an improved radiation technique may provide a safe and effective solution.

Implantation of the nitinol stent has improved angioplasty outcomes for occlusion of the femoropopliteal arteries, increasing the use of this minimally invasive alternative to surgery. However, stents also exhibit a high rate of in-stent stenosis — new narrowing within the stent due to the vessel’s exaggerated wound healing response. Endovascular brachytherapy is one option for treating this condition.

In some vessels, such as the coronary arteries, radiation localized to the treatment area has been able to prevent recurrent restenosis. Unlike coronary stents, however, femoropopliteal stents have not shown improved response to radiation in the past; results were similar to those after performing angioplasty alone.

The authors of an article in the current issue of the Journal of Endovascular Therapy evaluated the effectiveness of endovascular brachytherapy using liquid beta-emitting rhenium-188 delivered in an angioplasty balloon, an improvement over earlier delivery methods. The balloon provides more accurate dose control than previous catheter techniques. In the clinical setting, the use of beta radiation also offers logistical advantages over the gamma radiation used in previous trials.

Ninety patients underwent angioplasty and endovascular brachytherapy for long-segment in-stent stenosis in the femoropopliteal segment. The treated stents were open in 95 percent of the cases at six months after brachytherapy and in 80 percent at one year. Only nine patients experienced in-stent stenosis and 10 had reocclusion of the treated segment of the artery. At 12 months, 62 percent of the patients showed clinical improvement.

For more information: http://jevt.org/toc/enth/19/4


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now